S. Madge (London, United Kingdom), F. Ringshausen (Hannover, Germany)
Introduction
S. Madge (London, United Kingdom), F. Ringshausen (Hannover, Germany)
|  |
Early-infection Pseudomonas aeruginosa isolates from Cystic Fibrosis patients have high levels of LasB elastase activity
A. Llanos (Labège, France), P. Achard (Labège, France), C. Lozano (Labège, France), J. Bousquet (Labège, France), M. Zalacain (Labège, France), H. Guet-Revillet (Toulouse, France), M. Murris-Espin (Toulouse, France), M. Mittaine (Toulouse, France), M. Everett (Labège, France)
|    |
Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): final results of a long-term safety study using US CF Foundation Patient Registry and UK CF Patient Registry data
C. Kim (Boston, United States), S. Tian (Boston, United States), R. Zahigian (Boston, United States), A. Elbert (Bethesda, United States), S. Charman (London, United Kingdom), S. Carr (London, United Kingdom), D. Nazareth (Liverpool, United Kingdom)
| |
Triple CFTR modulator therapy is associated with improved endocrine pancreatic function in patients with cystic fibrosis
C. Steinack (Zurich , Switzerland), T. Gaisl (Zurich, Switzerland), F. Beuschlein (Zurich, Switzerland), S. Macé Matthew (Zurich , Switzerland), M. Ernst (Zurich , Switzerland)
| |
The effect of triple therapy cystic fibrosis transmembrane conductance regulator (CFTR) modulation on anxiety in people with cystic fibrosis
O. O'Carroll (Dublin 4, Ireland), C. Mc Keown (Dublin 4, Ireland), J. Bell (Dublin 4, Ireland), T. Nicholson (Dublin 4, Ireland), C. Gallagher (Dublin 4, Ireland), E. Mc Kone (Dublin 4, Ireland)
| |
Elexacaftor tezacaftor ivacaftor therapy alters plasma sphingolipid profiles in people with cystic fibrosis
D. Westhölter (Essen, Germany), F. Schumacher (Berlin, Germany), N. Wülfinghoff (Essen, Germany), S. Sutharsan (Essen, Germany), S. Strassburg (Essen, Germany), B. Kleuser (Berlin, Germany), P. Horn (Essen, Germany), S. Reuter (Essen, Germany), E. Gulbins (Essen, Germany), C. Taube (Essen, Germany), M. Welsner (Essen, Germany)
| |
Impacts of air pollution on the pulmonary morbidity of Cystic Fibrosis: an experimental study
M. Blayac (F-94000 Créteil, France), C. Yegen (F-94000 Créteil, France), E. Al Marj (F-75013 Paris, France), M. Cazaunau (F-94010 Créteil, France), A. Bergé (F-75013 Paris, France), R. Souktani (F-94000 Créteil, France), P. Coll (F-75013 Paris, France), S. Lanone (F-94000 Créteil, France)
| |
Modelling the behaviour of the mucus layer in the small airways
J. Shemilt (Manchester, United Kingdom), A. Horsley (Manchester, United Kingdom), O. Jensen (Manchester, United Kingdom), A. Thompson (Manchester, United Kingdom), C. Whitfield (Manchester, United Kingdom)
| |
Discussion
| |